A Phase 3 interventional study of Cabozantinib tablets and Placebo tablets in Hepatocellular Carcinoma, sponsored by Exelixis. Completed at 104 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-06.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing cabozantinib in Carcinoma, Hepatocellular — 7 open to participants now, 11 under way, 2 of them phase 3. cabozantinib · Carcinoma, Hepatocellular.
Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, this one is the 5th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 3rd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.
Browse Carcinoma, Hepatocellular studies →7 of the 27 studies testing cabozantinib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
University of California, Irvine · Sites in United States
Ages 18+
Humanity & Health Medical Group Limited · Sites in Hong Kong
Ages 18+
Anwaar Saeed · Sites in United States
Ages 18+
Exelixis · Sites in United States
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 20 · Phase 3 3 · Phase 4 1
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 707 is above the median of 54 across 2,619 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 35 across the 27 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 27 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 6 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
1 of the studies testing cabozantinib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04472767University of California, IrvineCabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing cabozantinib in Carcinoma, Hepatocellular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Select Inclusion Criteria:
Select Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cabozantinib (XL184) 60 mg tablet once daily
Drug: Cabozantinib tablets
Oral cabozantinib-matched placebo tablet once daily
Drug: Placebo tablets
Also known as: XL184
Overall Survival (OS)
The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.
Time frame: Up to 45 months
Progression-Free Survival (PFS)
Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.
Time frame: Up to 45 months
Objective Response Rate (ORR)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment (up to 45 months)
First patient enrolled: 26 September 2013, Data cut-off date: 01 June 2017
| Milestone | Cabozantinib (XL184) | Placebo |
|---|---|---|
| Started | 470 | 237 |
| Completed | 73 | 26 |
| Not completed | 397 | 211 |
| Withdrew: Adverse event | 98 | 11 |
| Withdrew: Clinical deterioration | 72 | 38 |
| Withdrew: Lack of efficacy | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Withdrawal by subject | 11 | 6 |
| Withdrew: Progressive disease | 206 | 152 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: No study treatment given | 3 | 0 |
The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.
| months | Cabozantinib (XL184) | Placebo |
|---|---|---|
| Overall Survival (OS) | 10.2 (9.1 to 12.0) | 8.0 (6.8 to 9.4) |
Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.
| months | Cabozantinib (XL184) | Placebo |
|---|---|---|
| Progression-Free Survival (PFS) | 5.2 (4.0 to 5.5) | 1.9 (1.9 to 1.9) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Participants | Cabozantinib (XL184) | Placebo |
|---|---|---|
| Objective Response Rate (ORR) | 18 | 1 |
Collected over Up to 61 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib (XL184) | 314/467 (67.2%) | 232/467 (49.7%) | 445/467 (95.3%) |
| Placebo | 167/237 (70.5%) | 87/237 (36.7%) | 173/237 (73%) |
| Event | Cabozantinib (XL184) | Placebo |
|---|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 39/467 | 22/237 |
| Abdominal PainGastrointestinal disorders | 6/467 | 9/237 |
| General physical health deteriorationGeneral disorders | 17/467 | 8/237 |
| PneumoniaInfections and infestations | 16/467 | 6/237 |
| Hepatic failureHepatobiliary disorders | 8/467 | 8/237 |
| Hepatic encephalopathyNervous system disorders | 15/467 | 1/237 |
| AscitesGastrointestinal disorders | 12/467 | 3/237 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/467 | 2/237 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 7/467 | 5/237 |
| AstheniaGeneral disorders | 9/467 | 0/237 |
| Event | Cabozantinib (XL184) | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 251/467 | 43/237 |
| Decreased appetiteMetabolism and nutrition disorders | 224/467 | 43/237 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 217/467 | 12/237 |
| FatigueGeneral disorders | 209/467 | 70/237 |
| NauseaGastrointestinal disorders | 147/467 | 41/237 |
| HypertensionVascular disorders | 137/467 | 13/237 |
| VomitingGastrointestinal disorders | 118/467 | 24/237 |
| Aspartate aminotransferase increasedInvestigations | 103/467 | 27/237 |
| AstheniaGeneral disorders | 99/467 | 17/237 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 90/467 | 5/237 |
| Age, Continuous(years) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| Median | 64.0 (22 to 86) | 64.0 (24 to 86) | 64.0 (22 to 86) |
| Age, Customized(Participants) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| Age, Customized — < 65 years old | 240 | 124 | 364 |
| Age, Customized — 65 to < 75 years old | 158 | 75 | 233 |
| Age, Customized — 75 to < 85 years old | 67 | 35 | 102 |
| Age, Customized — ≥ 85 years old | 5 | 3 | 8 |
| Sex: Female, Male(Participants) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| Female | 91 | 35 | 126 |
| Male | 379 | 202 | 581 |
| Ethnicity (NIH/OMB)(Participants) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 12 | 30 |
| Not Hispanic or Latino | 417 | 215 | 632 |
| Unknown or Not Reported | 35 | 10 | 45 |
| Race (NIH/OMB)(Participants) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 159 | 82 | 241 |
| Native Hawaiian or Other Pacific Islander | 3 | 0 | 3 |
| Black or African American | 8 | 11 | 19 |
| White | 264 | 130 | 394 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 36 | 13 | 49 |
| Geographic Region(Participants) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| Australia / New Zealand | 15 | 11 | 26 |
| Asia | 116 | 59 | 175 |
| Europe | 231 | 108 | 339 |
| North America (USA / Canada) | 108 | 59 | 167 |
| Presence of extrahepatic spread of disease and/or macrovascular invasion (stratification per IxRS)(Participants) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| Yes | 368 | 186 | 554 |
| No | 102 | 51 | 153 |
| Etiology of disease (stratification factor per IxRS),(Participants) | Cabozantinib (XL184) | Placebo | Total |
|---|---|---|---|
| HBV (with or without known HCV) | 182 | 90 | 272 |
| HCV (without known HBV) | 100 | 51 | 151 |
| Other (neither HBV nor HCV) | 188 | 96 | 284 |
6 further baseline measures are reported on the registry.
Showing the first 100 of 104 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Sep 2013, a primary completion of Oct 2017 and a completion of Jan 2021. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib